Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apalutamide + Maximal Tumor Eradication in Oligometastatic Prostate Cancer
NCT06972511Phase 3Recruiting
- Sponsor
- Renji Hospital
- Start
- Aug 2023
- Primary completion
- Dec 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of apalutamide in prostate cancer (PCa), sponsored by Renji Hospital. Started Aug 2023; status: recruiting.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06972511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06972511.